313.76MMarket Cap-8404P/E (TTM)
2.180High2.055Low326.39KVolume2.060Open1.990Pre Close695.17KTurnover0.26%Turnover RatioLossP/E (Static)145.26MShares3.33552wk High4.11P/B273.96MFloat Cap1.58052wk Low--Dividend TTM126.84MShs Float7.950Historical High--Div YieldTTM6.28%Amplitude0.530Historical Low2.129Avg Price1Lot Size
Immutep Stock Forum
MT Newswires· 8 mins ago
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For Anti-PD-1 Therapy
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, and sta...
No comment yet